Endo International PLC upsized a previously announced private offering of notes by $500 million to $1.5 billion.
The Dublin-based drugmaker is offering 7.500% senior secured notes due 2027 at an issue price of $1,000 per $1,000 principal amount.
Endo plans to use net proceeds to fund tender offers by unit Endo Finance LLC and purchase a portion of the company's outstanding senior unsecured notes, as well as to reduce Endo's outstanding indebtedness.
S&P Global Ratings lowered the issue-level rating on Endo's senior secured debt to B+ from BB- following the initial refinancing announcement.
This S&P Global Market Intelligence news article may contain information about credit ratings issued by S&P Global Ratings. Descriptions in this news article were not prepared by S&P Global Ratings.